REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

11 Mar 2024 06:00:23 By Nasdaq GlobeNewswire

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

08 Mar 2024 06:00:26 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

28 Feb 2024 08:48:56 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 Feb 2024 08:48:37 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

23 Feb 2024 08:45:04 By NetDania Notify

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation

23 Feb 2024 00:00:00 By Nasdaq GlobeNewswire

Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

21 Feb 2024 06:00:13 By Nasdaq GlobeNewswire

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

15 Feb 2024 23:59:00 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

06 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

02 Feb 2024 05:30:01 By Nasdaq GlobeNewswire

Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

02 Feb 2024 05:00:04 By Nasdaq GlobeNewswire

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

30 Jan 2024 06:00:41 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

25 Jan 2024 13:29:00 By Nasdaq GlobeNewswire

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

24 Jan 2024 11:00:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement

16 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024

05 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

18 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year

11 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes

10 Dec 2023 18:30:00 By Nasdaq GlobeNewswire

Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes

10 Dec 2023 11:30:00 By Nasdaq GlobeNewswire